{
  "url": "https://openlegislation.uk/prescription-only-medicines-human-use-amendment-order-1999/note",
  "json_url": "https://openlegislation.uk/prescription-only-medicines-human-use-amendment-order-1999/note.json",
  "legislation": "uksi/1999/1044",
  "legislation_title": "The Prescription Only Medicines (Human Use) Amendment Order 1999",
  "legislation_url": "https://openlegislation.uk/prescription-only-medicines-human-use-amendment-order-1999",
  "path": "note",
  "kind": "note",
  "number": null,
  "heading": "Explanatory note",
  "text": "(This note is not part of the Order)\nThis Order amends the Prescription Only Medicines (Human Use) Order 1997 (“the principal Order”) which specifies descriptions and classes of prescription only medicines (i.e. medicinal products which, subject to exemptions, may be sold or supplied by retail only with a prescription given by an appropriate practitioner and which may be administered only by or in accordance with the directions of such a practitioner). Under the principal Order, products are included in a class of medicines by reason of the substances contained in them, subject to their being excluded in specified circumstances.\nThe amendments made by this Order are as follows—\nAmendments to the conditions under which Aspirin may be sold or supplied otherwise than as a prescription only medicine (to permit containers or packages holding up to 100 tablets or capsules of non-effervescent Aspirin, at 75 mg strength, to be so sold or supplied), and the insertion of conditions under which Hydrocortisone in combination with Nystatin may be so sold or supplied (for the treatment of intertrigo).\nAmendment to the conditions under which Beclomethasone Dipropionate may be sold or supplied otherwise than as a prescription only medicine, correcting an error in the principal Order;\nThe inclusion in Schedule 1 to the principal Order of the substances Candesartan Cilexetil, Lornoxicam, Losartan Potassium, Nebivolol Hydrochloride, Nisoldipine, Propiverine Hydrochloride, Quetiapine Fumarate and Tacalcitol Monohydrate.\nAn assessment of the cost to business of complying with this Order has been made, copies of which have been placed in the libraries of both Houses of Parliament. Further copies may be obtained from the Department of Health, Medicines Control Agency, Information Centre, Room 1207 Market Towers, 1 Nine Elms Lane, London SW8 5NQ.",
  "extent": null,
  "status": null,
  "version": "current",
  "annotations": [],
  "outstanding_effects": [],
  "provenance": {
    "source": "legislation.gov.uk",
    "source_url": "https://www.legislation.gov.uk/uksi/1999/1044/note",
    "retrieved_at": "2026-10-29T10:51:43.182020+00:00"
  },
  "licence": "Open Government Licence v3.0",
  "licence_url": "https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/",
  "attribution": "Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives."
}